Table 2. Frequency and Proportion of Treated Patients Receiving Sipuleucel-T.
Study Year | No. Receiving Any Therapy (nā=ā7272)a | No. (%) Receiving Sipuleucel-T Therapy (nā=ā730) |
---|---|---|
2010 | 643 | 4 (0.6) |
2011 | 710 | 76 (10.7) |
2012 | 918 | 139 (15.1) |
2013 | 1110 | 132 (11.9) |
2014 | 1393 | 147 (10.6) |
2015 | 1421 | 139 (9.8) |
2016 | 1077 | 93 (8.6) |
Includes any treatment for metastatic castration-resistant prostate cancer (sipuleucel-T, abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, or radium 223).